Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation
Here, we report the case of a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient's decis...
Saved in:
Main Authors: | Sonia Brugnara (Author), Mariacristina Sicher (Author), Elena Maria Bonandini (Author), Davide Donner (Author), Franca Chierichetti (Author), Mattia Barbareschi (Author), Carlo Renè Girardelli (Author), Orazio Caffo (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2018-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report
by: Sonia Brugnara, et al.
Published: (2019) -
The combination of dabrafenib/trametinib is approved for the treatment of pediatric glioma
by: article Editorial
Published: (2023) -
Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma
by: Mélanie Saint-Jean, et al.
Published: (2018) -
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
by: Bárbara Lima, et al.
Published: (2022) -
BRAFV600E and KIT immunoexpression in early-stage melanoma
by: Andressa Germano, et al.